Le Meur, Yannick http://orcid.org/0000-0001-8913-415X
Nowak, Emmanuel
Barrou, Benoit
Thierry, Antoine
Badet, Lionel
Buchler, Matthias
Rerolle, Jean-Philippe
Golbin, Leonard
Duveau, Agnès
Dantal, Jacques
Merville, Pierre
Kamar, Nassim
Demini, Leïla
Zal, Franck
Funding for this research was provided by:
Direction Générale de l’offre de Soins (PHRC national 2019)
Hemarina
Article History
Received: 21 February 2023
Accepted: 6 April 2023
First Online: 1 May 2023
Declarations
:
: The study will be conducted in full compliance with the amended Declaration of Helsinki and with the Harmonized Tripartite Guideline for Good Clinical Practice in the European Community (CPMP/ICH/135/95). It was approved by an independent ethics committee and other relevant authorities (EUDRACT 2019-A00621-56).
: Not applicable.
: The authors declare the following financial interests/personal relationships that may be considered potential competing interests: Franck Zal is the founder of and holds stock in HEMARINA, the company that produces M101. Leila Demini is a collaborator of HEMARINA and does not have HEMARINA stock. Yannick Le Meur received consulting fees from HEMARINA. The other authors declare that they have no competing interests.